Advance Search
WU Lijie, DONG Fa. Effect and safety of L-carnitine in the treatment of chronic heart failure[J]. Journal of Clinical Medicine in Practice, 2020, 24(2): 104-107. DOI: 10.7619/jcmp.202002030
Citation: WU Lijie, DONG Fa. Effect and safety of L-carnitine in the treatment of chronic heart failure[J]. Journal of Clinical Medicine in Practice, 2020, 24(2): 104-107. DOI: 10.7619/jcmp.202002030
shu

Effect and safety of L-carnitine in the treatment of chronic heart failure

  • 1. The First Department of Cardiology;

  • 2. The Seventh Department of Cardiology, Xianyang Hospital of Yan'an University, Xianyang, Shaanxi, 712000

More Information
  • Received Date: November 10, 2019
  • Available Online: August 26, 2020
  • Published Date: August 26, 2020
    Graphical Abstract
    • Abstract
  • Objective To explore efficacy and safety of L-carnitine in the treatment of chronic heart failure(CHF). Methods Totally 120 patients with CHF were randomly divided into control group(n=60)and observation group(n=60). The control group was treated with conventional anti-CHF drugs, while the observation group was treated with L-carnitine injection on the basis of the control group. Both groups were continuously treated for 14 days. The clinical efficacy, serum N-terminal pro-brain natriuretic peptide(NT-proBNP), galectin-3(Gal-3)and carbohydrate antigen 125(CA125)levels, left ventricular ejection fraction(LVEF), left ventricular internal diameter(LVID)and the maximum distance of 6-min walking test(6MWT)were compared between the two groups. Adverse reactions were recorded. Results The total effective rate of the observation group was significantly higher than that of the control group(91.67% vs. 71.67%, P<0.05). After treatment, levels of serum NT-proBNP, Gal-3 and CA125 and LVID in the observation group were significantly lower than those in the control group, while LVEF and 6MWT were significantly higher than the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups during treatment(21.67% in the observation group vs. 16.67% in the control group, P>0.05). Conclusion L-carnitine is effective in the treatment of CHF, which can effectively reduce the expression levels of serum NT-proBNP, Gal-3 and CA125, improve cardiac function, and it is safe in clinical use.
    • FullText(HTML)
    • References (20)
  • Saitoh M, Dos Santos M R, Emami A, et al. Anorexia, functional capacity, and clinical outcome in patients with chronic heart failure: results from the Studies Investigating Co‐morbidities Aggravating Heart Failure(SICA‐HF)[J]. Esc Heart Fail, 2017, 4(4): 448-457.
    Halon D A, Ayman J, Rubinshtein R, et al. Cardiac Computed Tomography Angiographic Findings as Predictors of Late Heart Failure in an Asymptomatic Diabetic Cohort: An 8-Year Prospective Follow-Up Study[J]. Cardiology, 2017, 138(4): 218-227.
    Steinbeck L, Ebner N, Valentova M, et al. Detection of muscle wasting in patients with chronic heart failure using C-terminal agrin fragment: results from the Studies Investigating Co-morbidities Aggravating Heart Failure(SICA-HF)[J]. Europ J Heart Fail, 2016, 17(12): 1283-1293.
    潘月娟, 卢方平. 大剂量左卡尼汀在不能耐受血液透析的尿毒症合并心脏病患者中的应用[J]. 中华医学杂志, 2017, 97(48): 3792-3795.
    陈见红, 陈宇, 汪彪, 等. 高敏肌钙蛋白T在老年慢性心力衰竭与急性心肌梗死鉴别诊断中的价值[J]. 中国老年学, 2017, 37(5): 1150-1151.
    中华医学会心血管病学分会. 中国心力衰竭诊断和治疗指南2014[J]. 中华心血管病杂志, 2014, 42(2): 3-10.
    丁勇, 杨秀玲. 左卡尼汀联合辅酶Q10治疗重症慢性心力衰竭的临床疗效及安全性评价[J]. 中国临床药理学杂志, 2015, 31(20): 1993-1995.
    Travers J G, Kamal F A, Valiente-Alandi I, et al. Pharmacological and Activated Fibroblast Targeting of Gβγ-GRK2 After Myocardial Ischemia Attenuates Heart Failure Progression[J]. J Am Coll Cardiol, 2017, 70(8): 958-971.
    Piek A, Meijers W C, Schroten N F, et al. HE4 Serum Levels Are Associated with Heart Failure Severity in Patients With Chronic Heart Failure[J]. J Card Fail, 2017, 23(1): 12-19.
    杨继雷, 姚秀叶, 谷伟, 等. 参麦注射液联合左卡尼汀对慢性肺源性心脏病心肺功能的影响[J]. 中国临床药理学杂志, 2016, 32(5): 396-398.
    王真真, 刘地川, 杨刚. 别嘌呤醇在心力衰竭大鼠能量代谢中的保护作用[J]. 临床心血管病杂志, 2015, 31(1): 89-93.
    Miyata M, Yoshihisa A, Yamauchi H, et al. Impact of sleep-disordered breathing on myocardial damage and metabolism in patients with chronic heart failure[J]. Heart Vess, 2015, 30(3): 318-324.
    Carubelli V, Castrini A I, Lazzarini V, et al. Amino acids and derivatives, a new treatment of chronic heart failure[J]. Heart Fail Rev, 2015, 20(1): 39-51.
    Mohsen S, Nasrollah A, Maryam A. Effects of a family centered program on perceived social support in patients with congestive heart failure: An interventional study[J]. J Educ Health Promot, 2016, 5(1): 6-12.
    黄波, 丁跃有, 曹佳齐, 等. 促红细胞生成素结合左卡尼汀对老年慢性心衰合并贫血患者心功能的影响[J]. 中国老年学, 2015, 35(23): 6741-6742.
    沈红枫, 夏海江. 左卡尼汀注射液联合阿托伐他汀钙片治疗慢性心力衰竭的临床研究[J]. 中国临床药理学杂志, 2017, 33(5): 395-398.
    Perreault S, Denus S D, White M, et al. Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality: β -Blockers and Risk of Mortality[J]. Pharmacoepidemiology and Drug Safety, 2017, 26(1): 81-90.
    顾驾云, 夏海莲, 王芳芳, 等. 外周血半乳糖凝集素-3、N末端B型利钠肽原在慢性心力衰竭患者中的表达及意义[J]. 实用临床医药杂志, 2017, 21(5): 26-28.
    姜锋, 刘颖望, 周安, 等. 糖类抗原125与N末端B型利钠肽原相结合在慢性心力衰竭中的应用[J]. 中国动脉硬化杂志, 2015, 23(9): 932-936.
    杨玲玲, 李树仁, 郝清卿, 等. 应用半乳糖凝集素-3、N末端B型利钠肽原和超声心动图评估心力衰竭患者心功能的比较研究[J]. 中国循环杂志, 2018, 33(3): 236-240.
    • Related Articles

  • Related Articles

    [1]ZHU Yongmei, DU Lin, WANG Dan. Relationships of urinary liver-type fatty acid-binding protein and serum galectin-3 with early renal dysfunction in gout patients[J]. Journal of Clinical Medicine in Practice, 2024, 28(18): 76-80. DOI: 10.7619/jcmp.20241618
    [2]LIU Xiaohong, LI Mei, WANG Fengyun, SI Yuchen, DU Xiaoli, SHI Liangliang, SHAO Haiou, CHEN Li, ZHANG Hongyan. Effect of modified Qiankun Yudan Decoction combined with leuprorelin acetate on serum carbohydrate antigen 125 and recurrence rate in patients with adenomyosis[J]. Journal of Clinical Medicine in Practice, 2023, 27(18): 133-137. DOI: 10.7619/jcmp.20231988
    [3]LIU Kun, JIAO Hongbin, YANG Qing. Value of magnetic resonance diffusion weighted imaging combined with carbohydrate antigen 125 in differential diagnosis of borderline ovarian tumor and epithelial ovarian cancer[J]. Journal of Clinical Medicine in Practice, 2023, 27(5): 31-36. DOI: 10.7619/jcmp.20223212
    [4]WANG Ruolin, GU Ning. Research progress in role of galectin-3 in heart failure[J]. Journal of Clinical Medicine in Practice, 2022, 26(3): 130-133, 138. DOI: 10.7619/jcmp.20214742
    [5]TAO Dan, GONG Wei, QIN Songbing, XU Xiaoting, ZHOU Juying, WANG Lili. Value of perioperative carcinoembryonic antigen combined with carbohydrate antigen 19-9 and carbohydrate antigen 125 in predicting prognosis of patients with colorectal cancer in stages Ⅰ to Ⅲ[J]. Journal of Clinical Medicine in Practice, 2021, 25(9): 46-51. DOI: 10.7619/jcmp.20210560
    [6]LING Jia, ZHUANG Xiaohua, KAN Lihong, CAI Zhenrong, ZHU Zhongsheng. Correlation between levels of serum procollagen Ⅲ N-terminal peptide and galectin 3 and cardiac function in elderly patients with intractable heart failure[J]. Journal of Clinical Medicine in Practice, 2020, 24(5): 14-17. DOI: 10.7619/jcmp.202005004
    [7]MIAO Yuli, YANG Weixia, FU Xin, SHI Congyan. Correlation between serum human epididymis protein 4, carbohydrate antigen 125, human cartilage glycoprotein 39 levels and pathological features in patients with ovarian cancer[J]. Journal of Clinical Medicine in Practice, 2020, 24(4): 26-30. DOI: 10.7619/jcmp.202004007
    [8]YU Yang, YANG Hongtao, LU Qingyu. Effect of heart pacemaker on preventing and terminating chronic arrhythmia and its influence on cardiac function[J]. Journal of Clinical Medicine in Practice, 2018, (1): 21-23. DOI: 10.7619/jcmp.201801007
    [9]CHENG Minqi. Value of detection of human epididymis secretory protein 4 and carbohydrate antigen 125 levels in diagnosis of patients with ovarian cancer[J]. Journal of Clinical Medicine in Practice, 2015, (1): 72-74. DOI: 10.7619/jcmp.201501022
    [10]JIANG Meiju, ZHANG Hui. Effect of metformin on carcino-embryonic antigen and carbohydrate antigen 125 of patients with type 2 diabetes mellitus[J]. Journal of Clinical Medicine in Practice, 2014, (23): 20-22. DOI: 10.7619/jcmp.201423007

  • Cited by

    Periodical cited type(14)

    1. 范鹏举，时雨. 左卡尼汀联合丙种球蛋白治疗重症肺炎致心力衰竭患儿的效果分析. 临床医学工程. 2023(02): 195-196 .
    2. 王敬怡. 左卡尼汀联合辅酶Q10治疗重症慢性心力衰竭的临床疗效及安全性. 中国实用医药. 2023(10): 101-103 .
    3. 姚丛刻. 左卡尼汀治疗慢性心力衰竭患者的临床疗效及其对心功能的影响. 临床合理用药杂志. 2022(06): 53-55 .
    4. 牛艺潼. 不同剂量呋塞米与安体舒通片联合治疗重度心力衰竭的疗效及安全性分析. 中国医药指南. 2022(19): 84-86 .
    5. 王文娟，闫彩影，王晶，韩立，刘琳琳，隋世华. 尼可地尔联合左卡尼汀对缺血性心力衰竭患者心室重构、心肌纤维化及血管新生影响. 创伤与急危重病医学. 2022(04): 272-277 .
    6. 翟召锋. 不同剂量左旋肉毒碱治疗维持性血液透析合并心力衰竭的临床疗效评价. 中国医药指南. 2022(24): 6-10 .
    7. 冯京京. 酒石酸美托洛尔片联合左卡尼汀注射液治疗慢性心力衰竭的效果分析. 实用中西医结合临床. 2022(14): 10-13 .
    8. 刘瑞勇. 左卡尼汀联合血液透析滤过治疗老年肾衰竭患者的效果. 中国民康医学. 2021(03): 38-40 .
    9. 卢晓操，王晓琳. 慢性心力衰竭患者微型营养评估与血红蛋白、NT-pro BNP关系及其预后评估价值分析. 宁夏医科大学学报. 2021(02): 124-128 .
    10. 王淋，李雪，朴惠顺，李敏，段成军. GC-MS法检测左卡尼汀中遗传毒性物质S-环氧氯丙烷. 中南药学. 2021(04): 727-729 .
    11. 韩勇，罗薇，王莉萍，李渊博，张园园. 左卡尼汀注射液对心力衰竭患者运动耐力、炎症因子水平的影响. 临床医学研究与实践. 2021(14): 48-50 .
    12. 张永满. 左卡尼汀治疗老年慢性心力衰竭的研究进展. 现代诊断与治疗. 2021(08): 1206-1207+1226 .
    13. 何琦，卢冬雪. 左卡尼汀配合辅酶Q10治疗重症心力衰竭疗效分析. 深圳中西医结合杂志. 2021(20): 189-191 .
    14. 郭冬慈，张宝桐. 左卡尼汀联合促红细胞生成素及蔗糖铁治疗尿毒症行血液透析伴有肾性贫血的效果. 中国当代医药. 2020(35): 25-28 .

    Other cited types(3)

Catalog

    Get Citation
    PDF
    XML
    Article views (464) PDF downloads (20) Cited by(17)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return